BGN4 Probiotic Trial Links Microbiome Shifts To Biomarker Changes

Key Takeaways

• BGN4 was not associated with significant changes in hs-CRP, BMI, or body fat percentage, but significant between-group differences were reported for zonulin, TNFα, and fasting insulin.
• Supplementation was associated with enrichment of Bacteroides coprocola, Bifidobacterium catenulatum group, Lactiplantibacillus plantarum group, and Prevotella stercorea, and several taxa were reported to correlate with metabolic and inflammatory parameters.
• No adverse effects were observed, and liver enzyme concentrations, blood pressure, and gastrointestinal symptoms remained stable during the 8-week trial.

Eight weeks of Bifidobacterium bifidum BGN4 in adults with excess adiposity was associated with a between-group zonulin difference of -1.61 ± 2.69 ng/mL versus placebo. Significant between-group differences were also reported for TNFα and fasting insulin. The primary outcome, hs-CRP, did not significantly change over the intervention. The findings centered on gut barrier-related and metabolic markers without a matching shift in the primary inflammatory endpoint. Overall, the pattern was selective across the measured domains.

The randomized, double-blind, placebo-controlled trial enrolled 60 adults with excess body fat, defined as at least 20% in males and 28% in females. Sex- and age-stratified randomization assigned 30 participants to each arm, where they received one daily capsule of B. bifidum BGN4 at 9 × 10^9 CFU or matched placebo. Fifty-eight participants completed follow-up, leaving 29 completers in each group at 8 weeks. hs-CRP was the primary outcome, and blood testing also assessed zonulin, TNFα, glucose, insulin, lipid profiles, and total antioxidant capacity. Fecal samples were used to assess microbiota composition in the study, alongside the inflammatory and metabolic measures.

Against placebo, BGN4 did not significantly change BMI, body fat percentage, or the primary outcome hs-CRP. The between-group difference for TNFα was -0.17 ± 0.26 pg/mL. The between-group difference for fasting insulin was -3.52 ± 10.25 μIU/mL. Glucose, lipid profiles, and total antioxidant capacity were also measured. The changes were limited to selected biomarkers rather than the broader set of study measures.

Changes in gut microbiome composition were reported alongside the serum findings. Supplementation was associated with enrichment of Bacteroides coprocola, Bifidobacterium catenulatum group, Lactiplantibacillus plantarum group, and Prevotella stercorea. The enrichment spanned both bifidobacterial and non-bifidobacterial taxa rather than a single isolated genus-level signal. Several microbial taxa also correlated with metabolic and inflammatory parameters measured during follow-up. These microbiome findings remained associative within the 8-week trial.

No adverse effects were observed over 8 weeks, and liver enzyme concentrations, blood pressure, and gastrointestinal symptoms remained stable. Fifty-eight participants completed follow-up in the placebo-controlled comparison. The authors concluded BGN4 may serve as a preventive strategy for metabolic disorders through maintenance of gut microbial balance and intestinal barrier integrity.